Blood viscosity is a key rheological measure that is a biomarker of hematological, cardiovascular, and inflammatory conditions. This systematic review analyzed the changing role of blood viscosity and its potential significance in clinical practice. We provide a comprehensive examination of diagnostic methods, ranging from gold-standard rotatory viscometers to novel point-of-care and microfluidic technologies, emphasizing the practical features for precise data interpretation. This comprehensive clinical study revealed unique hemorheological profiles of different clinical conditions and diseases, particularly emphasizing the genetic constitution of sickle cell disease, diabetes mellitus with vascular consequences, and other diseases and syndromes associated with hyperviscosity. We provide a new approach for assessing the clinical value of viscosity as a pathophysiological description, prognostic biomarker, and decision-making measure. The review emphasizes that although substantial evidence supports its prognostic significance, many deficiencies remain in the research results relating to viscosity-guided therapies to improve patient care outcomes. The integration of artificial intelligence, wearable monitoring, and customized hemorheology was analyzed with caution. This synthesis emphasizes the need for established methods, interdisciplinary cooperation, and focused clinical trials to convert blood rheological knowledge into clinical applications for precise blood and cardiovascular therapies.
BaskurtOKMeiselmanHJ. Blood rheology and hemodynamics. Semin Thromb Hemost2003; 29: 435–450.
2.
GyawaliPLillicrapTPEsperonCG, et al.Whole blood viscosity and cerebral blood flow in acute ischemic stroke. Semin Thromb Hemost2024; 50: 580–591.
3.
LoweGD. Blood viscosity and cardiovascular disease. Thromb Haemost1992; 67: 494–498.
4.
ErnstEWeihmayrTSchmidM, et al.Cardiovascular risk factors and hemorheology. Physical fitness, stress and obesity. Atherosclerosis1986; 59: 263–269.
5.
CiccoGPirrelliA. Emoreologia clinica ed ipertensione arteriosa [clinical hemorrheology and arterial hypertension]. Minerva Cardioangiol1993; 41: 213–223.
6.
LongJAUndarAManningKB, et al.Viscoelasticity of pediatric blood and its implications for the testing of a pulsatile pediatric blood pump. ASAIO J2005; 51: 563–566.
7.
ChienS. Shear dependence of effective cell volume as a determinant of blood viscosity. Science1970; 168: 977–979.
8.
StoneHOThompsonHKJrSchmidt-NielsenK. Influence of erythrocytes on blood viscosity. Am J Physiol1968; 214: 913–918.
9.
ChienSUsamiSDellenbackRJ, et al.Blood viscosity: influence of erythrocyte deformation. Science1967; 157: 827–829.
10.
LipowskyHH. Microvascular rheology and hemodynamics. Microcirculation2005; 12: 5–15.
11.
BrillRJonesD. The influence of hematocrit, temperature and shear rate on the viscosity of blood from a high-energy-demand teleost, the yellowfin tuna thunnus albacares. J Exp Biol1994; 189: 199–212.
12.
CokeletGR. The rheology of human blood. In: Biomechanics: its foundations and objectives. Englewood Cliffs, NJ: Prentice-Hall, 1972, pp.63–103.
13.
BrustMSchaeferCDoerrR, et al.Rheology of human blood plasma: viscoelastic versus Newtonian behavior. Phys Rev Lett2013; 110: 078305.
14.
BarabinoGAPlattMOKaulDK. Sickle cell biomechanics. Annu Rev Biomed Eng2010; 12: 345–367.
15.
MchedlishviliG. Disturbed blood flow structuring as critical factor of hemorheological disorders in microcirculation. Clin Hemorheol Microcirc1998; 19: 315–325.
BullBSChienSDormandyJA, et al.Guidelines for measurement of blood viscosity and erythrocyte deformability. Clin Hemorheol Microcirc1986; 6: 439–453.
18.
BaskurtOKBoynardMCokeletGC, et al.New guidelines for hemorheological laboratory techniques. Clin Hemorheol Microcirc2009; 42: 75–97.
19.
ShinSKuYParkMS, et al.Measurement of blood viscosity using a pressure-scanning capillary viscometer. Clin Hemorheol Microcirc2004; 30: 467–470.
20.
LeblondVKastritisEAdvaniR, et al.Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood2016; 128: 1321–1328.
21.
KoenigWSundMFilipiakB, et al.Plasma viscosity and the risk of coronary heart disease: results from the MONICA-Augsburg Cohort Study, 1984 to 1992. Arterioscler Thromb Vasc Biol1998; 18: 768–772.
22.
SequeiraMCMCaetanoFJPFareleiraJMNA. Capillary viscometry for routine measurements of Newtonian liquids. Int J Thermophys2024; 45: 18.
23.
EugsterMHäuslerKReinhartWH. Viscosity measurements on very small capillary blood samples. Clin Hemorheol Microcirc2007; 36: 195–202.
24.
VaidyanathanRYeoTLimCT. Microfluidics for cell sorting and single cell analysis from whole blood. Methods Cell Biol2018; 147: 151–173.
25.
KhnoufRKarasnehDAbdulhayE, et al.Microfluidics-based device for the measurement of blood viscosity and its modeling based on shear rate, temperature, and heparin concentration. Biomed Microdevices2019; 21: 80. Published 2019 Aug 15.
26.
RosenbluthMJLamWAFletcherDA. Analyzing cell mechanics in hematologic diseases with microfluidic biophysical flow cytometry. Lab Chip2008; 8: 1062–1070.
27.
Del GiudiceF. A review of microfluidic devices for rheological characterisation. Micromachines (Basel)2022; 13: 167. Published 2022 Jan 22.
28.
NittaNHommaK. Ultrasonic measurement of fluid viscosity for blood characterization. Jpn J Appl Phys2005; 44: 4602.
29.
ReidMHMackayRSLantzBM. Noninvasive blood flow measurements by Doppler ultrasound with application to renal artery flow determination. Invest Radiol1980; 15: 323–331.
30.
TripetteJNguyenLCAllardL, et al.In vivo venous assessment of red blood cell aggregate sizes in diabetic patients with a quantitative cellular ultrasound imaging method: proof of concept. PLoS One2015; 10: e0124712. Published 2015 Apr 23.
31.
PoeppingTLNikolovHNThorneML, et al.A thin-walled carotid vessel phantom for Doppler ultrasound flow studies. Ultrasound Med Biol2004; 30: 1067–1078.
32.
PandeyCMAugustineSKumarS, et al.Microfluidics based point-of-care diagnostics. Biotechnol J2018; 13: 10.1002/biot.201700047.
33.
ZengHZhaoY. On-chip blood viscometer towards point-of-care hematological diagnosis. In: 2009 IEEE 22nd international conference on micro electro mechanical systems. IEEE, 2009, pp.240–243.
34.
LuppaPBMüllerCSchlichtigerA, et al.Point-of-care testing (POCT): current techniques and future perspectives. Trends Analyt Chem2011; 30: 887–898.
35.
ConnesPRenouxCJolyP, et al.Vascular pathophysiology of sickle cell disease. Presse Med2023; 52: 104202.
36.
ConnesPAlexyTDetterichJ, et al.The role of blood rheology in sickle cell disease. Blood Rev2016; 30: 111–118.
37.
ChienS. Rheology of sickle cells and erythrocyte content. In: BessisMShohetSBMohandasN (eds) Red cell rheology. Berlin, Heidelberg: Springer, 1978, pp.279–299. 10.1007/978-3-642-67059-6_22.
38.
LemonneNLamarreYRomanaM, et al.Impaired blood rheology plays a role in the chronic disorders associated with sickle cell-hemoglobin C disease. Haematologica2014 May; 99: 74–75.
39.
RenouxCJolyPGauthierA, et al.Blood rheology in children with the S/β+-thalassemia syndrome. Clin Hemorheol Microcirc2018; 69: 207–214.
40.
LewVLBookchinRM. Ion transport pathology in the mechanism of sickle cell dehydration. Physiol Rev2005; 85: 179–200.
41.
HebbelRPYamadaOMoldowCF, et al.Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest1980; 65: 154–160.
42.
CharacheSTerrinMLMooreRD, et al.Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med1995; 332: 1317–1322.
43.
AdamsRJMcKieVCHsuL, et al.Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med1998; 339: 5–11.
44.
AtagaKIKutlarAKanterJ, et al.Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med2017; 376: 429–439.
45.
VichinskyEHoppeCCAtagaKI, et al.A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med2019; 381: 509–519.
46.
KésmárkyGKenyeresPRábaiM, et al.Plasma viscosity: a forgotten variable. Clin Hemorheol Microcirc2008; 39: 243–246.
47.
VekasiJMartonZSKesmarkyG, et al.Hemorheological alterations in patients with diabetic retinopathy. Clin Hemorheol Microcirc2001; 24: 59–64.
48.
WinocourPDBryszewskaMWatalaC, et al.Reduced membrane fluidity in platelets from diabetic patients. Diabetes1990; 39: 241–244.
49.
Le DévéhatCVimeuxMKhodabandehlouT. Blood rheology in patients with diabetes mellitus. Clin Hemorheol Microcirc2004; 30: 297–300.
50.
BodeWAFonkTVan der VeenEA, et al.Blood viscosity in diabetic retinopathy. Neth J Med1985; 28: 449–453.
51.
ShinSHKuYH. Hemorheology and clinical application: association of impairment of red blood cell deformability with diabetic nephropathy. Korea-Aust Rheol J2005; 17: 117–123.
52.
CiuffettiGMercuriMMannarinoE, et al.Peripheral vascular disease. Rheologic variables during controlled ischemia. Circulation1989; 80: 348–352.
53.
Berndt-ZipfelCMichelsonGDworakM, et al. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study. Cardiovasc Diabetol2013; 12: 59.
54.
Abdul-GhaniMPratoDChiltonS, et al.SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care2016; 39: 717–725.
55.
McCartyMFO'KeefeJHDiNicolantonioJJ. Pentoxifylline for vascular health: a brief review of the literature. Open Heart2016; 3: e000365. Published 2016 Feb 8.
56.
JunkerRHeinrichJUlbrichH, et al.Relationship between plasma viscosity and the severity of coronary heart disease. Arterioscler Thromb Vasc Biol1998; 18: 870–875.
57.
LoweGDLeeAJRumleyA, et al.Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol1997; 96: 168–173.
58.
ReschKL, et al.Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med1992; 117: 371–375.
59.
DaviesPF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med2009; 6: 16–26.
60.
SiljanderPRMunnixICSmethurstPA, et al.Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood2004; 103: 1333–1341.
61.
DormandyJA. Clinical significance of blood viscosity. Ann R Coll Surg Engl1970; 47: 211–228.
62.
CortiRBadimonJJ. Value or desirability of hemorheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials. Curr Opin Lipidol2001; 12: 629–637.
63.
MaierCLTruongADAuldSC, et al.COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?Lancet2020; 395: 1758–1759.
64.
KubánkováMHohbergerBHoffmannsJ, et al.Physical phenotype of blood cells is altered in COVID-19. Biophys J2021; 120: 2838–2847.
65.
GörlingerKDirkmannDGandhiA, et al.COVID-19-associated coagulopathy and inflammatory response: what do we know already and what are the knowledge gaps?Anesth Analg2020; 131: 1324–1333.
66.
CarforaVSpinielloGRicciolinoR, et al.Anticoagulant treatment in COVID-19: a narrative review. J Thromb Thrombolysis2021; 51: 642–648.
67.
KhamisFAl-ZakwaniIAl HashmiS, et al.Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis2020; 99: 214–218.
68.
SiddiqiHKMehraMR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant2020; 39: 405–407.
KastritisELeblondVDimopoulosMA, et al.Waldenström's macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol2018; 29: iv41–iv50.
71.
GertzMA. Acute hyperviscosity: syndromes and management. Blood2018; 132: 1379–1385.
72.
SpivakJL. Polycythemia Vera. Curr Treat Options Oncol2018; 19: 12. Published 2018 Mar 7.
73.
LemonneNMöckeschBCharlotK, et al.Effects of hydroxyurea on blood rheology in sickle cell anemia: a two-years follow-up study. Clin Hemorheol Microcirc2017; 67: 141–148.
74.
KennyMWMeakinMWorthingtonDJ, et al.Erythrocyte deformability in sickle-cell crisis. Br J Haematol1981; 49: 103–109.
MarchioliRFinazziGSpecchiaG, et al.Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med2013; 368: 22–33.
78.
D’AgostinoRBSrPencinaMJMassaroJM, et al.Cardiovascular disease risk assessment: insights from Framingham. Glob Heart2013; 8: 11–23.
79.
LiYTianXXLiuT, et al.Association between whole blood viscosity and arterial stiffness in patients with type 2 diabetes mellitus. Endocrine2015; 49: 148–154.
80.
LeeHHeoJLeeIH, et al.Association between blood viscosity and early neurological deterioration in lacunar infarction. Front Neurol2022; 13: 979073. Published 2022 Sep 20.
81.
ErnstE, et al.Hemorheological abnormalities in rheumatoid arthritis. Clin Hemorheol Microcirc1987; 7: 591–598.
82.
FelkerGMAdamsKFJrGattisWA, et al.Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol2004; 44: 959–966.
83.
SolimanAACsorbaRYilmazA, et al.Rheologic results and their correlation to hemostatic changes in patients with moderate and severe preeclampsia: an observational cross-sectional study. Clin Hemorheol Microcirc2015; 59: 1–15.
ConnesPRenouxCRomanaM, et al.Blood rheological abnormalities in sickle cell anemia. Clin Hemorheol Microcirc2018; 68: 165–172.
86.
Valério de ArrudaMCruz SilvaAFernandes GaldurózJC, et al.Standardization for obtaining blood viscosity: a systematic review. Eur J Haematol2021; 106: 597–605.
87.
International Council for Standardization in Haematology (ICSH). Recommendation for a selected method for the measurement of plasma viscosity. J Clin Pathol1984; 37: 1147–1152.
88.
American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care2024; 47: S20–S42.
89.
ArnettDKBlumenthalRSAlbertMA, et al.ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation2019; 140: e596–e646.
90.
PowersWJRabinsteinAAAckersonT, et al.Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2019; 50: e344–e418.
91.
RichardsRSNwoseEU. Blood viscosity at different stages of diabetes pathogenesis. Br J Biomed Sci2010; 67: 67–70.
92.
OstergaardLKristiansenSBAngleysH, et al.The role of capillary transit time heterogeneity in myocardial oxygenation and ischemic heart disease. Basic Res Cardiol2014; 109: 09.
93.
Vaz CarneiroA. Evidence-based hemorheology. Does it exist? Applying evidence from clinical studies to the individual patient. Clin Hemorheol Microcirc2016; 64: 551–555.
94.
ZhaoY, et al.In vivo blood viscosity characterization based on frequency-resolved photoacoustic measurement. Appl Phys Lett2018; 113.
95.
GalanzhaEIZharovVP. In vivo photoacoustic and photothermal cytometry for monitoring multiple blood rheology parameters. Cytometry A2011; 79: 746–757.
96.
YalcinOErmanAMuratliS, et al.Time course of hemorheological alterations after heavy anaerobic exercise in untrained human subjects. J Appl Physiol (1985)2003; 94: 997–1002.
97.
Gironella-TorrentMBergamaschiGSorkinR, et al.Viscoelastic phenotyping of red blood cells. Biophys J2024; 123: 770–781.
